Deubiquitinase JOSD2 stabilizes YAP/TAZ to promote cholangiocarcinoma progression.

Deubiquitinase JOSD2 stabilizes YAP/TAZ to promote cholangiocarcinoma progression.
复制标题

去泛素酶 JOSD2 稳定 YAP/TAZ 以促进胆管癌进展。

DOI:
10.1016/j.apsb.2021.04.003
复制
发表时间:
2021-12
期刊:
Acta pharmaceutica Sinica. B
影响因子:
--
通讯作者:
He Q
He Q
中科院分区:
其他
文献类型:
--
作者:
Qian M;Yan F;Wang W;Du J;Yuan T;Wu R;Zhao C;Wang J;Lu J;Zhang B;Lin N;Dong X;Dai X;Dong X;Yang B;Zhu H;He Q

文献摘要

参考文献

被引文献

相似文献

胆管癌(CCA)已成为一种难治性癌症,缺乏治疗方案。据报道,在CCA患者中常见的是Yes相关蛋白(雅普)和转录辅激活因子与PDZ结合基序(TAZ)的异常激活。然而,人们对这一机制的基本原理仍然知之甚少。去泛素化酶(DUB)被认为是维持蛋白质稳态的主要协调者。在这里,我们确定了Josephin结构域包含蛋白2(JOSD 2)作为一个重要的DUB的雅普/TAZ,维持蛋白水平,通过切割的多聚泛素链的去泛素化酶活性依赖性的方式。在体外和体内,JOSD 2的缺失促进了雅普/TAZ蛋白酶体的降解,并显著抑制CCA的增殖。进一步的分析强调了CCA患者样品中JOSD 2和雅普丰度之间的正相关性。本研究揭示了JOSD 2对雅普/TAZ蛋白稳定性的调节作用,并揭示了其在CCA恶性进展中的作用,为雅普/TAZ相关CCA患者提供了潜在的干预靶点。JOSD 2是一种去泛素化酶,通过裂解多聚泛素链增加雅普/TAZ丰度并加强其信号传导,显著促进胆管癌进展。
Cholangiocarcinoma (CCA) has emerged as an intractable cancer with scanty therapeutic regimens. The aberrant activation of Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ) are reported to be common in CCA patients. However, the underpinning mechanism remains poorly understood. Deubiquitinase (DUB) is regarded as a main orchestrator in maintaining protein homeostasis. Here, we identified Josephin domain-containing protein 2 (JOSD2) as an essential DUB of YAP/TAZ that sustained the protein level through cleavage of polyubiquitin chains in a deubiquitinase activity-dependent manner. The depletion of JOSD2 promoted YAP/TAZ proteasomal degradation and significantly impeded CCA proliferation in vitro and in vivo. Further analysis has highlighted the positive correlation between JOSD2 and YAP abundance in CCA patient samples. Collectively, this study uncovers the regulatory effects of JOSD2 on YAP/TAZ protein stabilities and profiles its contribution in CCA malignant progression, which may provide a potential intervention target for YAP/TAZ-related CCA patients. JOSD2, a deubiquitinating enzyme, increases YAP/TAZ abundance and reinforces their signaling through the cleavage of polyubiquitin chains, observably contributing to cholangiocarcinoma progression.
DOI: 10.1158/0008-5472.can-16-3413
发表时间: 2017-09-15
期刊: Cancer research
影响因子: 11.2
作者:
Toloczko A;Guo F;Yuen HF;Wen Q;Wood SA;Ong YS;Chan PY;Shaik AA;Gunaratne J;Dunne MJ;Hong W;Chan SW
通讯作者: Chan SW
BAP1 通过调节 ERK1/2 和 JNK/c-Jun 通路在肝内胆管癌中充当肿瘤抑制因子。
DOI: 10.1038/s41419-018-1087-7
发表时间: 2018-10-10
影响因子: 9
作者:
Chen XX;Yin Y;Cheng JW;Huang A;Hu B;Zhang X;Sun YF;Wang J;Wang YP;Ji Y;Qiu SJ;Fan J;Zhou J;Yang XR
通讯作者: Yang XR
DOI: 10.1073/pnas.1620306114
发表时间: 2017-05-02
影响因子: 11.1
作者:
Kim, Youngeun;Kim, Wantae;Jho, Eek-Hoon
通讯作者: Jho, Eek-Hoon
YAP 是人类胆管癌的关键癌基因
DOI: 10.18632/oncotarget.4043
发表时间: 2015-07-10
期刊: Oncotarget
影响因子: --
作者:
Pei T;Li Y;Wang J;Wang H;Liang Y;Shi H;Sun B;Yin D;Sun J;Song R;Pan S;Sun Y;Jiang H;Zheng T;Liu L
通讯作者: Liu L
DOI: 10.1038/s41568-019-0196-7
发表时间: 2019-11
期刊: Nature reviews. Cancer
影响因子: --
作者:
Bushweller JH
通讯作者: Bushweller JH